Field Trial Update

Plant Health Care PLC
09 January 2008



EMBARGOED: 09.00, 9 January 2008

                              PLANT HEALTH CARE PLC
                     ('Plant Health Care' or 'the Company')

                              Field Trials Update

  - Strong commercial field trial results in Harpin based N-Hibit and ProAct -

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, will announce today, at the Beltwide Cotton Conferences in
Nashville, Tennessee that results of replicated N-Hibit(R) and ProActTM field
trials in 2007 demonstrated yield improvements in cotton of between 6% and 12%
when used in combination with nematicides.

N-Hibit(R) and ProActTM are EPA registered, Harpin based products which have, in
field trials, consistently demonstrated their efficacy in improving crop yields
by reducing harmful cyst nematodes. Harpin proteins are produced by diseases
which are harmful to plants and, as a result, the application of a Harpin based
technology, such as N-Hibit(R) or ProActTM, causes the plant to behave as though
being attacked, even in the absence of disease pressure. Consequently, the plant
activates its natural self-defence and growth system, improving yield, root mass
and overall plant biomass.

Plant Health Care develops, manufacturers and markets a range of innovative
Harpin Protein-based products (Harp-N-Tek(R)). Harpin based proteins have
demonstrated a reduction in nematode populations by on average 50 percent, in
numerous replicated and commercial field testing work undertaken over several
years by leading university plant pathologists and nematologists, crop
consultants and cotton producers.

Commenting on the trials, John Brady, Chief Executive of Plant Health Care,
said:

'In the Company's interim results statement, the board highlighted its belief in
the substantial commercial potential for our Harpin technology and undertaking
trials is an important part of the development process. The agreement signed
with Monsanto in December 2007, was a significant step in developing this
exciting technology and the success of these trials further validates the
board's belief in its potential.'

'In demonstrating such strong yield improvements in these recent tests,
particularly in conjunction with other, already established and widely used
nematicides, the prospects for Harpin are further strengthened and the board
will continue to explore opportunities available to it in order to exploit fully
the potential of this exciting technology.'

                                     -Ends-

For further information please contact:

Plant Heath Care plc       Tavistock                 Evolution Securities
                           Communications            Limited
John Brady, Chief          Jeremy Carey/Matt         Tim Worlledge/ Tim
Executive                  Ridsdale                  Redfern
Tel: [phone]      Tel: [phone]        Tel: [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange